AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 3021189
Drug: Aspirin 30
RxNorm normalized name: aspirin 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 30 mg
Trial: 1745620
Drug: Cefepime 2
RxNorm normalized name: cefepime 2000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefepime 2 g every 12 hours plus metronidazole 500 mg every 6 hours intravenously
Trial: 1745620
Drug: Gentamicin 1.5
RxNorm normalized name: HYDROCORTISONE ACEPONATE 1.11 mg in 1 mL / MICONAZOLE NITRATE 17.4 mg in 1 mL / GENTAMICIN 1.5 mg in 1 mL AURICULAR (OTIC) SUSPENSION [EASOTIC]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin 1.5 mg/kg plus clindamycin 900 mg every 8 hours intravenously
Trial: 17152739
Drug: Ergotamine 1
RxNorm normalized name: ergotamine 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ergotamine 1 mg
Trial: 11903083
Drug: Metoclopramide 20
RxNorm normalized name: metoclopramide 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide 20 mg
Trial: 17152739
Drug: Ergotamine 1
RxNorm normalized name: ergotamine 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ergotamine 1 mg + Metoclopramide 20 mg
Trial: 17152739
Drug: Ergotamine 2
RxNorm normalized name: ergotamine 2 mg sublingual tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ergotamine 2 mg + Metoclopramide 20 mg
Trial: 27116364
Drug: Immediate treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate treatment group (two, 150-minute group sessions spaced one-week apart)
Trial: 23163910
Drug: linagliptin 10
RxNorm normalized name: empagliflozin-linagliptin 10 mg-5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: linagliptin 10 mg
Trial: 22145698
Drug: linagliptin 5
RxNorm normalized name: linagliptin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: linagliptin 5 mg, linagliptin 10 mg, placebo, voglibose
Trial: 177210
Drug: BCNU (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCNU (100 mg/m2 qd X 1) and procarbazine (100 mg/m2 qd X 14)
Trial: 177210
Drug: Previous combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Previous combination of procarbazine, CCNU, and vincristine
Trial: 25924819
Drug: Esomeprazole 20
RxNorm normalized name: esomeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 20 mg four times daily (q.i.d.)
Trial: 25924819
Drug: Esomeprazole 20
RxNorm normalized name: esomeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 20 mg two times a day (b.i.d.)
Trial: 21270789
Drug: Buprenorphine (B)
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Buprenorphine (B) 16 mg, n = 18
Trial: 21270789
Drug: Buprenorphine/Naloxone (B/N)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine/Naloxone (B/N) 16/4 mg, n = 16
Trial: 18650507
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg of simvastatin daily
Trial: 18650507
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg of simvastatin daily
Trial: 18650507
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (not specified dosage)
Trial: 6429852
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg 2% nitroglycerin ointment (Plantorgan Co.)
Trial: 6429852
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg 2% nitroglycerin ointment (Pohl Boskamp Co.)
Trial: 6429852
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg nitroglycerin in the transdermal therapeutic system (Ciba Geigy)
Trial: 30910440
Drug: GSP301 (665
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSP301 (665 μg of olopatadine and 25 μg of mometasone)
Trial: 30910440
Drug: Olopatadine (665
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olopatadine (665 μg)
Trial: 30910440
Drug: Mometasone (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mometasone (25 μg)
Trial: 29974521
Drug: α-lipoic acid
RxNorm normalized name: α-lipoic acid
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: α-lipoic acid (ALA) 600 mg intravenous before graft reperfusion
Trial: 29974521
Drug: α-lipoic acid
RxNorm normalized name: α-lipoic acid
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: α-lipoic acid (ALA) treatment
Trial: 23336412
Drug: Protein-free calf
RxNorm normalized name: thymus gland-calf
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein-free calf blood extract ophthalmic gel
Trial: 23336412
Drug: Recombinant bovine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant bovine basic fibroblast growth factor ophthalmic gel
Trial: 26907728
Drug: Fluticasone furoate
RxNorm normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluticasone furoate nasal spray
Trial: 12764120
Drug: Preconditioning with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preconditioning with sumatriptan (5‐HT(1B/1D) agonist) followed by placebo administration
Trial: 12764120
Drug: Verbal suggestions
RxNorm normalized name: HERBAL MISCELLANEOUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verbal suggestions of increase/decrease of growth hormone (GH) and cortisol
Trial: 9327315
Drug: Midazolam +
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam + Oral Transmucosal Fentanyl Citrate (OTFC)
Trial: 18157519
Drug: UDCA (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UDCA (300 mg/day)
Trial: 15753414
Drug: Risedronate (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate (2.5 mg daily for 12 months)
Trial: 12616667
Drug: Commercially prepared
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commercially prepared oral syrup
Trial: 12616667
Drug: Reference capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference capsule formulation
Trial: 10546521
Drug: Tamoxifen and/or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen and/or chemotherapy
Trial: 10546521
Drug: New cytotoxic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New cytotoxic drugs (taxanes, vinorelbine, capecitabine), high dose chemotherapy, immunotherapy with monoclonal antibodies (herceptin), gene therapeutic approaches
Trial: 10546521
Drug: Predictive factors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Predictive factors and biological markers
Trial: 6406616
Drug: Cefazolin prophylaxis
RxNorm normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefazolin prophylaxis (5 doses of 1g)
Trial: 23091128
Drug: Group G:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group G: inactivated Lactobacillus salivarius and sodium butyrate
Trial: 23091128
Drug: Groups D,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Groups D, E, and G
Trial: 23091128
Drug: Groups E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Groups E and G
Trial: 23091128
Drug: Groups B,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Groups B, C, E, G, and I after d 15
Trial: 23091128
Drug: Groups B,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Groups B, C, D, E, F, G, and H after d 45
Trial: 23091128
Drug: Groups F
RxNorm normalized name: Stomodine F
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Groups F and G at d 45
Trial: 17968180
Drug: Iloprost in
RxNorm normalized name: iloprost Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iloprost in saline solution for 3 weeks
Trial: 9425969
Drug: Spinal anesthesia
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal anesthesia with 3.4 mL of hypobaric 0.18% bupivacaine (6.12 mg)
Trial: 8483561
Drug: Epirubicin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin (100 mg/m2)
Trial: 8483561
Drug: FEM (5-fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FEM (5-fluorouracil 600 mg/m2, epirubicin 50 mg/m2, mitomycin 6 mg/m2)
Trial: 2961394
Drug: Epidural injections
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural injections
Trial: 26791805
Drug: Testofen (Trigonella
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testofen (Trigonella foenum-graecum seed extract) at a dose of 600 mg/day for 12 weeks
Trial: 23216401
Drug: Short-term individual
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term individual dynamic therapy
Trial: 23216401
Drug: Antidepressant medication
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant medication (augmented treatment)
Trial: 12814316
Drug: HA-coated threaded
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HA-coated threaded implants
Trial: 12814316
Drug: HA-coated cylindric
RxNorm normalized name: Imperata cylindrica root extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HA-coated cylindric implants
Trial: 12814316
Drug: machined Ti
FDA approved: no
EMA approved: no
PMDA approved: no
Description: machined Ti threaded implants
Trial: 9780560
Drug: Antiandrogen therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiandrogen therapy combined with radiation therapy
Trial: 28170391
Drug: Higher dose
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dose of primaquine (1 mg base/kg/day for 7 days)
Trial: 28170391
Drug: Standard high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard high dose of primaquine (0.5 mg base/kg/day for 14 days)
Trial: 21616170
Drug: 30 g
RxNorm normalized name: Lancet Unilet 30 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 g of milled flaxseed per day
Trial: 16765760
Drug: Repeat intramuscular
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeat intramuscular dose of 11.4 mg betamethasone (as Celestone Chronodose)
Trial: 14757602
Drug: Nebulized epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebulized epinephrine (0.9 mg/kg of 2.25% racemic epinephrine)
Trial: 14757602
Drug: Nebulized albuterol
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized albuterol (0.15 mg/kg of 0.5% albuterol sulfate)
Trial: 2963230
Drug: High-dose leucovorin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose leucovorin plus FUra (Arm B)
Trial: 2963230
Drug: Sequential methotrexate,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential methotrexate, FUra, leucovorin (Arm C)
Trial: 22820873
Drug: Waitlist (clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waitlist (clinical treatment as usual)
Trial: 21853859
Drug: Amino acid-carbohydrate
RxNorm normalized name: silk amino acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amino acid-carbohydrate (AACHO) prior to resistance exercise (979 kJ, 36 g carbohydrate, 22.5 g protein)
Trial: 18820657
Drug: Subconjunctival injection
RxNorm normalized name: STREPTOMYCES GRISEUS 0.05 g in 1 mL SUBCONJUNCTIVAL INJECTION, SOLUTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subconjunctival injection of 20 mg triamcinolone acetonide with topical 1% prednisolone acetate
Trial: 18820657
Drug: Intravenous injection
RxNorm normalized name: Meta Trace FDG, intravenous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of 500 mg methylprednisolone with topical 1% prednisolone acetate
Trial: 17302057
Drug: Drug-pair group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-pair group
Trial: 15118485
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg Delta-9-tetrahydrocannabinol (THC)
Trial: 15118485
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg THC combined with 5 mg cannabidiol (CBD)
Trial: 15118485
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg THC combined with 15 mg CBD
Trial: 9542820
Drug: Antihypertensive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive treatment (beta-adrenoceptor blockers and/or thiazide diuretics)
Trial: 2577394
Drug: Intraperitoneal (IP)
RxNorm normalized name: Intraperitoneal Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal (IP) administration of 30 mg/l vancomycin for 10 days
Trial: 2577394
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) administration of 1 gram of vancomycin (2 infusions: first on diagnosis day, second 7 days later)
Trial: 806789
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 0.10 mg reserpine, 10 mg mefruside, and 125 mg alpha-methyldopa
Trial: 806789
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 0.15 mg reserpine, 15 mg mefruside, and 150 mg inositol nicotinate
Trial: 28664349
Drug: Citrulline/Malate (stimol)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citrulline/Malate (stimol) 3 times a day as 1 g for breakfast, 1 g for lunch, and 1 g for dinner
Trial: 28664349
Drug: Placebo (same
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (same dosage and timing as stimol)
Trial: 26177810
Drug: Rivaroxaban 10
RxNorm normalized name: rivaroxaban 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 10 mg once a day for thromboprophylaxis
Trial: 26177810
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of deep and superficial blocks
Trial: 23169243
Drug: FIT in
RxNorm normalized name: First Aid Fit Industrial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FIT in combination with a feces collection paper (n=5129)
Trial: 18305080
Drug: Low-dose intrathecal
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose intrathecal opioid (LITO): morphine 5 microg kg(‐1) plus sufentanil 1 microg kg(‐1)
Trial: 18305080
Drug: High-dose intrathecal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intrathecal opioid (HITO): morphine 15 microg kg(‐1) plus sufentanil 1 microg kg(‐1)
Trial: 16421677
Drug: Lidocaine 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 1.0 mg.kg(‐1) (group L1)
Trial: 16421677
Drug: Lidocaine 1.5
RxNorm normalized name: LIDOCAINE 1.5%/EPI 1:200000 INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 1.5 mg.kg(‐1) (group L2)
Trial: 12742805
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (perindopril and indapamide)
Trial: 12953851
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (perindopril and indapamide) with recurrent stroke
Trial: 4008686
Drug: Formulation B
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation B (gelatin capsules containing microcrystalline 8‐MOP with particle size between 20 mu and 30 mu)
Trial: 4008686
Drug: Formulation C
RxNorm normalized name: Army Liposome Formulation component monophosphoryl lipid A
DrugBank: Monophosphoryl lipid A (DB19290)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation C (microcrystalline 8‐MOP in an emulsion base)
Trial: 4008686
Drug: Formulation A
RxNorm normalized name: meningococcal vaccine of unknown formulation and unknown serogroups
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation A (gelatin capsules containing 8‐MOP with a mean particle size of 200 mu)
Trial: 30208456
Drug: Levofloxacin prophylaxis
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levofloxacin prophylaxis during 2 chemotherapy cycles for acute leukemia (n=100)
Trial: 26421957
Drug: EE/GSD patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EE/GSD patch
Trial: 25453582
Drug: EE/NGMN patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EE/NGMN patch
Trial: 22198974
Drug: Inhaled mannitol,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled mannitol, 400 mg twice a day
Trial: 22198974
Drug: Inhaled mannitol,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled mannitol, 50 mg twice a day (control)
Trial: 16971160
Drug: Manual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual therapy dynamometer (100N force)
Trial: 11350770
Drug: Endurance training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endurance training combined with rhGH administration
Trial: 8198264
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg butorphanol (Group A)
Trial: 8198264
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg butorphanol (Group B)
Trial: 8198264
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg butorphanol (Group C)
Trial: 8198264
Drug: 3 mL
RxNorm normalized name: WATER,INHL 3 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mL normal saline (Group D)
Trial: 29696917
Drug: Acupuncture combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture combined with acupoint catgut embedding sequential therapy
Trial: 23678828
Drug: Alpha lipoic
RxNorm normalized name: Alpha Lipoic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha lipoic acid treatment for four months
Trial: 16800100
Drug: Nevirapine/lamivudine/stavudine combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nevirapine/lamivudine/stavudine combination tablet (200 mg/150 mg/30 mg)
Trial: 16800100
Drug: Nevirapine 200
RxNorm normalized name: nevirapine 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nevirapine 200 mg, Lamivudine 150 mg, and Stavudine 30 mg administered concurrently as separate formulations
Trial: 12903886
Drug: Gln-enriched enteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gln-enriched enteral nutrition (0.35 g gln/kg body weight/d)
Trial: 12903886
Drug: Standard enteral
RxNorm normalized name: Standard enteral formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard enteral formulation
Trial: 11191542
Drug: Monoclonal antibody
RxNorm normalized name: Monoclonal antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoclonal antibody to IL-5 (SB-240563) at 10 mg/kg
Trial: 11191542
Drug: Monoclonal antibody
RxNorm normalized name: Monoclonal antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoclonal antibody to IL-5 (SB-240563)
Trial: 9167750
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate (MTX) administered intravenously
Trial: 6418374
Drug: Oral trimethoprim-sulfamethoxazole
RxNorm normalized name: sulfamethoxazole / trimethoprim
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral trimethoprim-sulfamethoxazole plus erythromycin (TMZ-E)
Trial: 27317704
Drug: Levosimendan treatment
RxNorm normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levosimendan treatment
Trial: 20055785
Drug: Nitroimidazole antibiotics
RxNorm normalized name: 2-methyl-5-nitroimidazole-1-ethanol
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitroimidazole antibiotics (metronidazole, ornidazole)
Trial: 18522729
Drug: Combined written
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined written and oral information (N = 278)
Trial: 18522729
Drug: Oral information
RxNorm normalized name: Inflammation OTC Bruise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral information alone (N = 299)
Trial: 18522729
Drug: Combined written
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined written and oral information
Trial: 2039194
Drug: Temafloxacin 100
RxNorm normalized name: TEMAFLOXACIN
DrugBank: Temafloxacin (DB01405)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temafloxacin 100 mg
Trial: 1662885
Drug: Temafloxacin 200
RxNorm normalized name: TEMAFLOXACIN
DrugBank: Temafloxacin (DB01405)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temafloxacin 200 mg
Trial: 1662883
Drug: Temafloxacin 400
RxNorm normalized name: temafloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temafloxacin 400 mg
Trial: 1662880
Drug: Temafloxacin 600
RxNorm normalized name: temafloxacin 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temafloxacin 600 mg
Trial: 2039194
Drug: Temafloxacin 800
RxNorm normalized name: TEMAFLOXACIN
DrugBank: Temafloxacin (DB01405)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temafloxacin 800 mg
Trial: 2039194
Drug: Temafloxacin 1000
RxNorm normalized name: TEMAFLOXACIN
DrugBank: Temafloxacin (DB01405)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temafloxacin 1000 mg